Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in Sickle Cell Disease and Nephropathy (RESIST)
NCT06286046Phase 2Withdrawn
- Sponsor
- Agios Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mitapivat in sickle cell disease (SCD), nephropathy, sponsored by Agios Pharmaceuticals. Planned start Mar 2026; status: withdrawn.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)nephropathy
Beyond the preview
Go deeper on NCT06286046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06286046.